BR0116764A - moléculas isoladas compreendendo epitopos contendo porções sulfatadas, anticorpos para os referidos epitopos e seus usos - Google Patents

moléculas isoladas compreendendo epitopos contendo porções sulfatadas, anticorpos para os referidos epitopos e seus usos

Info

Publication number
BR0116764A
BR0116764A BRPI0116764-2A BR0116764A BR0116764A BR 0116764 A BR0116764 A BR 0116764A BR 0116764 A BR0116764 A BR 0116764A BR 0116764 A BR0116764 A BR 0116764A
Authority
BR
Brazil
Prior art keywords
epitopes
antibodies
isolated molecules
present
containing sulfated
Prior art date
Application number
BRPI0116764-2A
Other languages
English (en)
Inventor
Janette Lazarovits
Yocheved Hagai
Daniel Plaksin
Tikva Vogel
Abraham Nimrod
Hagit Mar-Haim
Tamar Richter
Boaz Amit
Lena Kooperman
Tuvia Peretz
Avigdor Levanon
Ester Szanthon
Original Assignee
Savient Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savient Pharmaceuticals Inc filed Critical Savient Pharmaceuticals Inc
Publication of BR0116764A publication Critical patent/BR0116764A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"MOLéCULAS ISOLADAS COMPREENDENDO EPITOPOS CONTENDO PORçõES SULFATADAS, ANTICORPOS PARA OS REFERIDOS EPITOPOS E SEUS USOS". A presente invenção fornece epitopos presentes em células cancerígenas e é importante no fenómeno fisiológico como o rolamento de células, metástase e inflamação. São fornecidos métodos e compostos terapêuticos e de diagnóstico que usam anticorpos capazes de se ligarem aos epitopos. Os métodos e compostos de acordo com a presente invenção podem ser usados no diagnóstico e na terapia para as referidas doenças como câncer, incluindo crescimento de tumor e metástase, leucemia, doença autoimune e doença inflamatória.
BRPI0116764-2A 2000-12-29 2001-12-31 moléculas isoladas compreendendo epitopos contendo porções sulfatadas, anticorpos para os referidos epitopos e seus usos BR0116764A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75118100A 2000-12-29 2000-12-29
US25894800P 2000-12-29 2000-12-29
PCT/US2001/049442 WO2002053700A2 (en) 2000-12-29 2001-12-31 Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof

Publications (1)

Publication Number Publication Date
BR0116764A true BR0116764A (pt) 2007-01-09

Family

ID=26946974

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0116764-2A BR0116764A (pt) 2000-12-29 2001-12-31 moléculas isoladas compreendendo epitopos contendo porções sulfatadas, anticorpos para os referidos epitopos e seus usos

Country Status (13)

Country Link
EP (1) EP1406930A4 (pt)
JP (1) JP2005503756A (pt)
KR (1) KR20030091953A (pt)
CN (1) CN100347194C (pt)
BR (1) BR0116764A (pt)
CA (1) CA2433225A1 (pt)
CZ (1) CZ20031982A3 (pt)
HU (1) HUP0700079A2 (pt)
IL (1) IL156689A0 (pt)
MX (1) MXPA03005945A (pt)
PL (1) PL366223A1 (pt)
RU (1) RU2003123101A (pt)
WO (1) WO2002053700A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
EP1551452A4 (en) * 2002-07-01 2006-08-30 Savient Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR THERAPEUTIC TREATMENT
MXPA06000252A (es) * 2003-06-30 2006-12-15 Bio Technology General Israel Anticuerpos y usos de los mismos.
WO2005005455A2 (en) * 2003-06-30 2005-01-20 Bio-Technology General (Israel)Ltd. Specific human antibodies
ITMI20031714A1 (it) * 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.
MY148646A (en) * 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
US20060003940A1 (en) * 2004-05-11 2006-01-05 Rong-Hwa Lin T-cell death-inducing epitopes
EP2637672B1 (en) 2010-11-12 2018-08-22 Gentium S.r.l. Defibrotide for use in prophylaxis and/or treatment of graft versus host disease (gvhd).
UA114712C2 (uk) 2011-06-13 2017-07-25 Абдженомікс Коеператіеф У.А. Моноклональне антитіло, яке імуноспецифічно зв'язується з людським psgl-1, та його застосування
CN104619857A (zh) 2012-06-22 2015-05-13 真蒂奥姆有限公司 用于测定去纤维蛋白多核苷酸的生物活性的基于优球蛋白的方法
WO2016013828A1 (ko) * 2014-07-21 2016-01-28 연세대학교 산학협력단 황산화된 더피 케모카인 수용체의 세포 외 도메인 1 변이체 및 이의 용도
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
JP2019031486A (ja) * 2017-08-04 2019-02-28 公立大学法人福島県立医科大学 新規ポリペプチド及びその用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3326693A (en) * 1991-12-12 1993-07-19 Scripps Research Institute, The Bifunctional antithrombotic molecules and antithrombotic polypeptides
KR19990022954A (ko) * 1995-06-14 1999-03-25 어니스트 엠. 해데드 Ｐ-셀렉틴 리간드 및 관련 분자 및 방법
EP0850243B1 (en) * 1995-08-03 2003-10-08 Board Of Regents Of The University Of Oklahoma o-glycan inhibitors of selectin mediated inflammation
US5985833A (en) * 1996-09-17 1999-11-16 Wisconsin Alumni Research Foundation Thrombin inhibitor
AU773542B2 (en) * 1998-06-16 2004-05-27 Board Of Regents Of The University Of Oklahoma, The Glycosulfopeptides and methods of synthesis and use thereof

Also Published As

Publication number Publication date
PL366223A1 (en) 2005-01-24
CA2433225A1 (en) 2002-07-11
CN100347194C (zh) 2007-11-07
JP2005503756A (ja) 2005-02-10
IL156689A0 (en) 2004-01-04
WO2002053700A3 (en) 2004-02-12
HUP0700079A2 (en) 2007-05-02
CN1649900A (zh) 2005-08-03
EP1406930A2 (en) 2004-04-14
KR20030091953A (ko) 2003-12-03
RU2003123101A (ru) 2005-03-10
WO2002053700A2 (en) 2002-07-11
CZ20031982A3 (cs) 2004-09-15
MXPA03005945A (es) 2004-10-15
EP1406930A4 (en) 2007-01-10

Similar Documents

Publication Publication Date Title
BR0116764A (pt) moléculas isoladas compreendendo epitopos contendo porções sulfatadas, anticorpos para os referidos epitopos e seus usos
BR0009537A (pt) Composições para tratamento e diagnóstico de câncer de mama e métodos para seu uso
DK1633784T3 (da) OVR110 antistofsammensætninger og -anvendelsesfremgangsmåder
DK2289D0 (da) Monoklonale antistoffer samt deres fremstilling og anvendelse
HUP0102992A3 (en) Antibodies to the ed-b domain of fibronectin, conjugates containing them and use therefor for diagnosis and therapy of tumors and diseases associated with angiogenesis
NO20021992D0 (no) Anti-prostatastamcelleantigen(PSCA)-antistoffpreparat og fremgangsmåter for anvendelse
ATE110172T1 (de) Antikörper gegen menschlichen progesteronrezeptor sowie diagnosematerial und -verfahren.
DE122004000040I1 (de) Therapeutische Zusammensetzungen die monoklonale Antikörper enthalten gegen den menschlichen Rezeptor für epidermalen Wachstumsfaktor.
ATE229073T1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
MEP35308A (en) COMPOUNDS SPECIFIC TO ADENOSINE A1, A2a, AND A3 RECEPTOR AND USES THEREOF
NZ591137A (en) Methods and systems for predicting response of cells to a therapeutic agent
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
WO2005046573A3 (en) Pro104 antibody compositions and methods of use
ATE294591T1 (de) Verwendung von trifunktionellen bispezifischen und trispezifischen antikörpern zur behandlung von malignem aszites
TR200002218T2 (tr) 2-(Pürin-9-il)-Tetrahidrofüran -3,4-Diol türevleri
CY1108489T1 (el) Παραγωγη τετρασθενων αντισωματων
BR9710811A (pt) Fragmentos de liga-Æo de antigeno que detecta especificamente c-lulas cancerigenas nucleotideos que codificam os fragmentos e o seu uso para a profilaxia e detec-Æo de c-nceres
TR200001250T2 (tr) Ati-CD40L bileşikleri ile lupus nefritis tedavisi
MX2007006355A (es) Epitopes antigenos de interleucina-21, anticuerpos relacionados y su uso en el campo medico.
BR0312483A (pt) Anticorpos e seus usos
SE8404283L (sv) Anvendning av ett specifikt tumorassocierat antigen, nemligen sialosyllaktotetraos, for diagnostiska och terapeutiska forfaranden vid cancersjukdomar
ATE348112T1 (de) Krebserkrankungen modifizierende antikörper
ATE248189T1 (de) Antikörper gegen vasp (vasodilator-stimulated phosphoprotein), hybridomzellen für deren gewinnung, und deren verwendung
NO330924B1 (no) Isolert antistoff eller antistoffragment, immunokonjugat, anvendelse av et immunokonjugat, en terapeutisk effektiv mengde av et immunokonjugat eller et antistoff eller antistoffragment for fremstilling av preparater henholdsvis for selektiv odeleggelse av celler, behandling av en sykdomstilstand eller diagnostisering av metastaser eller prostatakreft, samt pavisningsmetode.
WO2005080426A3 (en) Protein ligands for nkg2d and ul16 receptors and uses thereof

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008 POR TER SIDO APRESENTADO PROTOCOLO DE ESCLARECIMENTO NO 420805107402 EM 18/08/2008.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE 8.6 DA RPI 2112 DE 28/06/2011.